Inactivated Vaccines Market Outlook Highlights The Next Major Growth Opportunities
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Inactivated Vaccines Market Forecast: What Market Value Is Expected By 2030?
The market for inactivated vaccines has experienced consistent expansion in recent times. Valued at $6.37 billion in 2025, it is projected to reach $6.61 billion by 2026, reflecting a compound annual growth rate (CAGR) of 3.9%. Historical growth has been driven by several factors, including an increase in the prevalence of infectious diseases, progress in the field of virology research, financial backing from governments for immunization efforts, the broadening of healthcare facilities, and initiatives aimed at raising public awareness about the importance of vaccination.
The market for inactivated vaccines is projected to experience robust expansion over the coming years. By 2030, its value is anticipated to reach $8.07 billion, reflecting a compound annual growth rate (CAGR) of 5.1%. This forecasted growth is driven by several factors, including a rising elderly population, improved healthcare access in emerging economies, technological progress in vaccine delivery methods, a surge in worldwide immunization efforts, and the growing use of multi-dose and combination vaccines. Key trends shaping this period involve innovations in vaccine formulation, enhanced cold chain infrastructure, a heightened need for pediatric vaccines, strengthened government-backed immunization programs, and the creation of novel combination vaccines.
Download A Free Sample Report For Comprehensive Market Insights:
Inactivated Vaccines Market Growth Drivers And Industry Catalysts
The growing incidence of infectious diseases is anticipated to drive the expansion of the inactivated vaccine market in the coming years. Infectious diseases refer to illnesses caused by pathogens like bacteria, viruses, fungi, or parasites, which can be transmitted between individuals, leading to various symptoms and health issues. Tuberculosis serves as an example of such an infectious disease. Inactivated vaccines utilize non-living pathogens to trigger an immune response, offering effective protection against conditions such as polio, hepatitis A, and influenza. For example, in November 2023, an article from the Centers for Disease Control and Prevention, a U.S.-based national public health agency, reported that tuberculosis cases in the United States rose from 8,320 in 2022 to 9,615 in 2023, reflecting an increase of 1,295 cases. Consequently, the rising prevalence of infectious diseases is fueling growth in the inactivated vaccine market.
Inactivated Vaccines Market Segment Analysis Highlighting Growth Areas
The inactivated vaccines market covered in this report is segmented –
1) By Type: Viral Vaccine, Bacterial Vaccine
2) By Method Of Inactivation: Solvent Detergent, Radiation, pH Concentration, Heat Inactivation, Other Methods Of Inactivation
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
Subsegments:
1) By Viral Vaccine: Inactivated Poliovirus Vaccine (IPV), Inactivated Influenza Vaccine, Inactivated Hepatitis A Vaccine, Inactivated Rabies Vaccine
2) By Bacterial Vaccine: Inactivated Typhoid Vaccine, Inactivated Cholera Vaccine, Inactivated Pertussis Vaccine, Inactivated Plague Vaccine
Inactivated Vaccines Market Trends Influencing Long-Term Demand
Key players in the inactivated vaccines industry are prioritizing product introductions and clearance from regulators to reinforce their worldwide vaccine pipelines and address the growing demand for immunization services. To illustrate, in April 2024, Sanofi S.A., a healthcare firm based in France, rolled out Verorab, its inactivated rabies shot, across the UK for all age categories, applicable to both pre-exposure and post-exposure scenarios. This release underscores the organization’s sustained dedication to broadening its catalog of inactivated vaccines and boosting its international immunization capabilities. Furthermore, it signals heightened financial commitments and accelerating regulatory efforts related to the creation and endorsement of inactivated vaccines. With an increasing number of companies pushing similar products forward and expanding their inventories, these coordinated actions are fueling notable expansion in the inactivated vaccines sector, thereby fostering improved protection against infectious illnesses.
Inactivated Vaccines Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the inactivated vaccines market are Pfizer Inc., Sinopharm Group Co. Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, CSL Limited, Daiichi Sankyo Company Limited, Zydus Lifesciences Ltd., Sinovac Biotech Ltd., Biological E Limited, Hualan Biological Engineering Inc., Shenzhen Kangtai Biological Products Co. Ltd., Serum Institute of India Pvt. Ltd., Beijing Tiatan Biological Products Co. Ltd., Valneva SE, Beijing Minhai Biotechnology Co. Ltd., Bharat Biotech International Limited, Panacea Biotec Ltd., Sinergium Biotech SA, Bharat Immunologicals and Biologicals Corporation Limited, Haffkine Biopharmaceutical Corporation Limited, Incepta Vaccine Ltd., Changchun BCHT Biotechnology Co. Ltd.
Access The Complete Inactivated Vaccines Market Report:
Inactivated Vaccines Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the inactivated vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inactivated vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
